e 4031 has been researched along with alpha-naphthoflavone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kovalenko, A; Krasavin, M; Lukin, A; Moore, D; Tikhonova, IG; Zahanich, I; Zhurilo, N; Zozulya, S | 1 |
| Bae, S; Cho, Y; Choi, J; Kang, JA; Kim, YC; Lee, D; Lim, C; Park, M; Park, SG; Seo, J | 1 |
2 other study(ies) available for e 4031 and alpha-naphthoflavone
| Article | Year |
|---|---|
Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold.
Topics: Amides; Animals; Drug Delivery Systems; Humans; Hypoglycemic Agents; Mice; Microsomes, Liver; Molecular Docking Simulation; Protein Binding; Receptors, G-Protein-Coupled; Thiadiazoles | 2016 |
Entry inhibition of hepatitis B virus using cyclosporin O derivatives with peptoid side chain incorporation.
Topics: Antiviral Agents; Cyclosporins; Hepatitis B; Hepatitis B virus; Humans; Imidazoles; Liver Neoplasms; Organic Anion Transporters, Sodium-Dependent; Peptoids; Sulfonamides; Symporters; Thiophenes; Virus Internalization | 2022 |